KRYSKrystal Biotech, Inc.
Price
+103%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, no red flags, demanding price, growing in the filings, the market undecided.
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Krystal Biotech, Inc. (KRYS) reported revenue of $119M in Q2 2026 (quarter ended Jun 30, 2026), up 24% from the same quarter a year earlier. That came with net income of $55M (46% of revenue). For the full year FY2025, revenue was $389M (+34% year on year) and net income $205M. Its largest region in Q2 2026 was United States at $92M, 77% of the disclosed total, well ahead of Europe at 16%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results.Earnings release · press release
- Jul 21, 2026On July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis.Other event · Form 8-K
- May 4, 2026Krystal Biotech Announces First Quarter 2026 Financial and Operating Results.Material event (exhibits only) · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $119.2MThe company’s own SEC segment disclosure.
- United States$91.6M77%
- Europe$19.3M16%
- Japan$8.3M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.